The weak market of January was replaced by a first week of February that can only be described as one massive snapback rally. Investors have demonstrated for more than two years now that they will buy big dips and overlooked value in stocks when they can. 24/7 Wall St. reviews dozens of analyst calls each day of the week for new ideas and overlooked gems for its readers. The reality is that most analyst calls have upside price targets of 10% to 30%, but that does not apply to small-cap and low-priced stocks.

When possible, 24/7 Wall St. accumulates and publishes summaries of the most aggressive analyst calls. That, of course, includes small-cap and low-priced stocks. You just do not get calls for a stock to rise 50%, 100% or more in Dow and S&P 500 stocks. In fact, only three of the S&P 500 stocks are up 100 in the trailing 52-weeks — one due to a merger premium. This week we tracked only five analyst calls in stocks that were under $10, down from eight picks in the prior week.

While investors often get excited about the low-priced and small-cap stocks, 24/7 Wall St. cannot emphasize enough that these are generally far riskier than most Dow and S&P 500 stocks. Many investors think that all small-cap or mid-cap stocks grow up to be large-cap stocks. This is a myth, and some companies flounder forever — or worse, some companies die. Lastly, low-priced and small-cap stocks are completely inappropriate for conservative and even moderately conservative investors.

ALSO READ: 11 IPOs Scheduled for Next Week

The five analyst picks under $10 featured by 24/7 Wall St. this week are ImmunoGen Inc. (NASDAQ: IMGN), Sirius XM Holdings Inc. (NASDAQ: SIRI), MEI Pharma Inc. (NASDAQ: MEIP), Westell Technologies Inc. (NASDAQ: WSTL) and Yamana Gold Inc. (NYSE: AUY).

ImmunoGen

Oppenheimer raised ImmunoGen to Outperform from Perform on Friday. What stands out is the $11 price target, which implies upside of 50% from the current $7.32 price. Immunogen’s consensus price target is much lower than Oppenheimer’s at $8.35, but the highest listed analyst price target is also $12.00.

Oppenheimer said that recent weakness around disappointing results from Marianne brings a buying opportunity ahead of a what it called a “catalyst-rich next 12 months” in IMGN-853 in folate-receptor-positive, platinum-resistant ovarian cancer and/or endometrial cancer as the primary value driver going forward.

Oppenheimer further said it assigns $8 of its $11 target to the “853 opportunity for sales above $600 million — and this eclipses the $3 per share value of Kadcyla royalties.” Oppenheimer even indicated upside to its $11 price target in the call.

Sirius XM

Perhaps the most well-known stock of all those featured, the satellite radio monopoly saw its price target raised to $5 from $4.50 at Maxim Group when the firm reiterated its Buy rating. This implies 34% upside from the $3.72 close, but it also ties the highest listed analyst price target. If Maxim is not good enough, the much more well-known Merrill Lynch, which also has the highest $5 price target, said that subscriber growth shows no sign of stalling when it reiterated its Buy rating and slightly raised its targets and buyback expectations for 2015.

ALSO READ: Insiders Aggressively Buy Shares as Market Rockets Higher

For whatever this is worth, Thomson Reuters still lists the lowest price target on Sirius as only $3.50, implying very little downside, if you trust analysts that is. Just do not hold too much water on that “analyst floor target” if another serious market correction comes up.

MEI Pharma

This one far from a household name, and we must warn that it has a market cap of only $86 million. Late this week, Wells Fargo initiated coverage on this oncology-focused therapeutics player. What stands out is that Wells Fargo assigned a monster valuation range of $10 to $11, based on a sum of the parts. This represents 150% upside to the $10 part of the call, versus the $4.00 recent closing bell price. The stock has a 52-week range of $3.57 to $13.98, and we found it interesting that this is said to be the lowest price target of the other handful of analysts that cover it.

The Wells Fargo call on MEI Pharma said that Pracinostat and Vidaza are ushering in a new era of MDS and AML. The report said:

MEI’s lead drug HDAC inhibitor pracinostat has generated compelling, albeit early, clinical responses, astounding molecular remissions, and a good tolerability profile (as compared to other HDACi’s) in combination with Vidaza in MDS in a study conducted at MD Anderson and more recently in 1st Line elderly AML (at ASH 2014), and HMA-refractory MDS.

One warning: some approvals are not expected until 2019 or 2020.

Westell Technologies

On Friday, Northland Securities maintained this stock as Outperform. The price target was lowered slightly, to $2.25 from $2.50. Usually we would avoid calls of this sort, but the $1.26 closing price on Friday implies an upside of almost 80%. As far as we can tell, this may be the only active analyst call on Westell.

ALSO READ: J.P. Morgan Still Has 3 Gold Stocks to Buy

Be advised that Westell’s most recent report, from February 4, said that revenue was being affected by carrier spending slowdowns and capital spending delays. Despite saying that it thinks 2015 is off to a good start, Westell is laying off workers and consolidating its facilities of operation.

The market cap of $75.6 million for the telephone products company compared to its last quarter sales of only $14 million, and the stock’s 52-week range is $0.96 to $4.73. This stock reached above $30 a long time ago — during the tech bubble of 2000.

Yamana Gold

Merrill Lynch resumed coverage of Yamana this week with a Buy rating, after a recent equity issuance. After shares dropped over 7% to $4.15 on Friday, along with gold, this implies exactly 50% upside expected to the firm’s $6.25 price objective.

Merrill Lynch reported that Yamana is entering a period of strong free cash flow generation of $272 million in 2015 and $295 million in 2016, versus negative $208 million or so in 2014. The report also indicated that Yamana is trading at a 28% discount to its peers on a price to net asset value basis. The fresh share issuance also let Merrill Lynch take down its forecast for the end 2015 and 2016 on net debt to $1.3 billion in 2015 and $1.1 billion in 2016 from prior respective targets of $1.1 billion and $1.6 billion.

ALSO READ: Credit Suisse’s Top 2015 Picks: Tesla, Micron, Southwest and More

Last weekend, 24/7 Wall St. featured 8 analyst stock picks under $10 with huge upside. These included Genworth Financial, Groupon, JA Solar, Ruckus Wireless and more.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.